EMEA-003623-PIP01-24
      Submitted by Anonymous (not verified) on 11 June 2025 - 14:24    
  
  EMEA-003623-PIP01-24
EMEA-003623-PIP01-24
EMEA-003624-PIP01-24
EMEA-003573-PIP01-23
EMEA-003570-PIP01-23
EMEA-003567-PIP01-23
EMEA-003448-PIP01-23
Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0111/2024
EMEA-003566-PIP01-23
Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0109/2024
EMEA-003546-PIP01-23